PE20091180A1 - Tratamientos terapeuticos contra el cancer - Google Patents

Tratamientos terapeuticos contra el cancer

Info

Publication number
PE20091180A1
PE20091180A1 PE2008002178A PE2008002178A PE20091180A1 PE 20091180 A1 PE20091180 A1 PE 20091180A1 PE 2008002178 A PE2008002178 A PE 2008002178A PE 2008002178 A PE2008002178 A PE 2008002178A PE 20091180 A1 PE20091180 A1 PE 20091180A1
Authority
PE
Peru
Prior art keywords
against cancer
therapeutic treatments
cancer
treatments against
treatment
Prior art date
Application number
PE2008002178A
Other languages
English (en)
Spanish (es)
Inventor
Robert Ross
John Macdougall
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40824720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091180(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Publication of PE20091180A1 publication Critical patent/PE20091180A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2008002178A 2007-12-27 2008-12-23 Tratamientos terapeuticos contra el cancer PE20091180A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1716007P 2007-12-27 2007-12-27
US11896908P 2008-12-01 2008-12-01

Publications (1)

Publication Number Publication Date
PE20091180A1 true PE20091180A1 (es) 2009-08-26

Family

ID=40824720

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002178A PE20091180A1 (es) 2007-12-27 2008-12-23 Tratamientos terapeuticos contra el cancer

Country Status (16)

Country Link
US (1) US20090181997A1 (enExample)
EP (1) EP2225254A4 (enExample)
JP (1) JP2011522773A (enExample)
KR (1) KR20100137416A (enExample)
CN (1) CN101918420A (enExample)
AR (1) AR070047A1 (enExample)
AU (1) AU2008345151A1 (enExample)
BR (1) BRPI0821779A2 (enExample)
CA (1) CA2710377A1 (enExample)
CL (1) CL2008003901A1 (enExample)
IL (1) IL206632A0 (enExample)
MX (1) MX2010006991A (enExample)
PE (1) PE20091180A1 (enExample)
TW (1) TW200934784A (enExample)
WO (1) WO2009086416A1 (enExample)
ZA (1) ZA201004403B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
EP2389068A4 (en) * 2009-01-23 2012-07-18 Cancer Rec Tech Ltd HEMGE OF THE HEDGEHOG SIGNAL PATH
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
BR112012004149A2 (pt) 2009-08-25 2016-03-22 Abraxis Bioscience Llc terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
US20120010230A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
RU2492855C2 (ru) * 2011-02-15 2013-09-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" СО РАМН (ФГБУ "НИИ онкологии" СО РАМН) Способ комбинированного лечения немелкоклеточного рака легкого ii и iii стадии с пред- и послеоперационной химиотерапией
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
JP6815331B2 (ja) * 2015-04-21 2021-01-20 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN107137406B (zh) * 2016-03-01 2021-07-02 江苏恒瑞医药股份有限公司 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途
CN109803660A (zh) * 2016-08-10 2019-05-24 细胞基因公司 复发性和/或难治性实体瘤和非霍奇金淋巴瘤的治疗
PE20200010A1 (es) 2017-04-03 2020-01-06 Hoffmann La Roche Anticuerpos que se unen a steap-1
US11478469B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
CA3095699A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
AU2019315466B2 (en) 2018-07-31 2022-05-19 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CN115282133A (zh) * 2021-12-06 2022-11-04 温州医科大学 竹红菌乙素在制备抗结肠癌药物中的应用
AU2024207913A1 (en) * 2023-01-12 2025-07-31 Sol-Gel Technologies Ltd. Treatment and prevention of basal cell carcinoma with topical composition comprising patidegib

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US6238876B1 (en) * 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
AU755943B2 (en) * 1998-08-13 2003-01-02 University Of Southern California Methods to increase blood flow to ischemic tissue
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20070021493A1 (en) * 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE60028411T2 (de) * 1999-10-13 2007-01-04 Johns Hopkins University School Of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
US6552016B1 (en) * 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
IL133809A0 (en) * 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
US6613798B1 (en) * 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
US7708998B2 (en) * 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
AU2002247847A1 (en) * 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
JP2003192919A (ja) * 2001-10-17 2003-07-09 Asahi Denka Kogyo Kk 難燃性合成樹脂組成物
GB0221539D0 (en) * 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
US20080118493A1 (en) * 2003-07-15 2008-05-22 Beachy Philip A Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity
US20080095761A1 (en) * 2003-10-01 2008-04-24 The Johns Hopkins University Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis
US20070231828A1 (en) * 2003-10-01 2007-10-04 Johns Hopkins University Methods of predicting behavior of cancers
US20080057071A1 (en) * 2003-10-20 2008-03-06 Watkins David N Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
ES2578728T3 (es) * 2004-08-27 2016-07-29 Infinity Pharmaceuticals, Inc. Proceso para la preparación de compuestos análogos de ciclopamina
WO2006039569A1 (en) * 2004-09-30 2006-04-13 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006124700A2 (en) * 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
EP2314289A1 (en) * 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
WO2007076294A2 (en) * 2005-12-15 2007-07-05 Wei Chen Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease
ATE533497T1 (de) * 2005-12-27 2011-12-15 Genentech Inc Verfahren zur verwendung von hedgehog-kinase- antagonisten zur behandlung von hedgehog- vermittelten krebs
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2007123511A2 (en) * 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
SG175691A1 (en) * 2006-10-31 2011-11-28 Us Gov Health & Human Serv Smoothened polypeptides and methods of use
WO2008057497A2 (en) * 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
TWI433674B (zh) * 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101687877B (zh) * 2007-03-07 2014-07-23 无限发现股份有限公司 杂环环杷明类似物及其使用方法
EP2134719B1 (en) * 2007-03-07 2013-07-17 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
PE20090806A1 (es) * 2007-04-18 2009-06-27 Merck & Co Inc Derivados de triazol que son antagonistas de smo
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
CA2709203A1 (en) * 2007-12-13 2009-06-18 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
WO2009086451A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100222287A1 (en) * 2007-12-27 2010-09-02 Mcgovern Karen J Therapeutic Cancer Treatments
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CL2009001479A1 (es) * 2008-07-02 2010-01-04 Infinity Pharmaceuticals Inc Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
US20120010230A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers

Also Published As

Publication number Publication date
BRPI0821779A2 (pt) 2019-09-24
CL2008003901A1 (es) 2009-07-24
CA2710377A1 (en) 2009-07-09
CN101918420A (zh) 2010-12-15
KR20100137416A (ko) 2010-12-30
MX2010006991A (es) 2010-09-30
AU2008345151A1 (en) 2009-07-09
TW200934784A (en) 2009-08-16
JP2011522773A (ja) 2011-08-04
ZA201004403B (en) 2012-02-29
AR070047A1 (es) 2010-03-10
EP2225254A1 (en) 2010-09-08
WO2009086416A1 (en) 2009-07-09
IL206632A0 (en) 2010-12-30
EP2225254A4 (en) 2011-03-30
US20090181997A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
DOP2012000155A (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
PA8850801A1 (es) Compuestos útiles para inhibir chk1
DOP2009000243A (es) Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
PA8740901A1 (es) Compuestos organicos
CO6592104A2 (es) Compuesto heterociclico
CL2008003901A1 (es) Uso de un inhibidor de hedgehog para extender la sobrevida libre de recidiva en un paciente con cancer, que se encuentra en quimioterapia o ha sido tratado previamente con quimioterapia.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
UY31432A1 (es) Compuestos de diarilhidantoina
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
AR067769A1 (es) Derivado de ditiazol para el tratamiento del cancer
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
NI201000051A (es) Benzotiazoles como moduladores del receptor de grelina.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
CR20110687A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
MX2011006532A (es) Compuestos anticancerigenos.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
EA201070295A1 (ru) Лечение рака легких

Legal Events

Date Code Title Description
FC Refusal